Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 30 years, using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, Genentech is among the world's leading biotech companies, with multiple products on the market and more than 100 projects in the pipeline. For more general information about the company, visit our corporate overview section.

In March 2009, Genentech became a wholly owned member of the Roche Group. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech's South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech Research and Early Development operates as an independent center within Roche.

Press releases and filings related to the Roche merger.

Committed to being a strong and engaged corporate citizen, Genentech supports a wide variety of organizations and initiatives through our corporate giving programs.